Haemonetics P/E Ratio

Haemonetics (HAE) currently reports a P/E ratio of 58.08. That is below the Healthcare sector average of 70.94. Use the charts on this page to explore Haemonetics's P/E ratio history and peer comparisons.

Haemonetics's P/E ratio of 58.08 is lower than the Healthcare sector average of 70.94. That is roughly 18.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Haemonetics's market price to a fundamental measure such as earnings, sales, or book value. At 58.08, HAE can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 58.08, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 70.94. From there, open related valuation or income-statement pages for Haemonetics, and consider following HAE for alerts when major investors trade the stock.

Haemonetics is classified in the Healthcare sector. On P/E ratio, it currently shows 58.08 versus a sector average near 70.94. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HAE with unrelated industries.